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  For relevant Imatinib therapy against Philadelphia (Ph)-positive leukemias, it is 
essential to monitor mutations in the chimerical bcr-abl tyrosine kinase domain 
(TKD). However, there is no universally acceptable consensus on how to 
efficiently identify mutations in the target TKD. Recently, high-resolution melting 
(HRM) technology was developed, which allows gene scanning using an 
inexpensive generic heteroduplex-detecting dsDNA binding dye. This study 
aimed to validate HRM’s introduction in a practical clinical setting for screening 
of mutations in sporadic sites of the chimerical bcr-abl TDK.  All chimerical and 
wild-type abl TKD regions selectively amplified were used for HRM assays and 
direct sequencing. The HRM test had approximately 2.5 to 5% detection 
sensitivity for mutations. In contrast to mixture samples with mutant and 
wild-type cells, all mutant cell samples had indeterminate melting curves 
equivalent to those of the wild-type due to formation of only a homodulex. This 
issue was improved by the addition of exogenous wild-type DNA after PCR. 
Subsequently, HRM results gave a high accordance rate of 98.7% (44/45 
samples) compared to the sequencing data. The discordant results in the one 
appear to be due to unsuccessful amplification. Thus, HRM is thought to be 
suitable for reliable scanning for mutations in the chimerical abl TDK in a clinical 
setting.  
 







 The small chemical agent of Imatinib has a high therapeutic response rate for 
diseases carrying the chimerical bcr-abl gene. For example, the first Imatinib 
treatment was reported to give approximately 80% and 60% complete molecular 
response rates in chronic myelogeneuos leukemia (CML) and Philadelphia 
(Ph)-positive acute lymphoblastic leukemia (ALL), respectively1,2). However, in 
many cases mutations in the chimerical abl Tyrosine kinase domain (TKD) were 
revealed to precede resistance to Imatinib, resulting in disease relapse and 
progression to advanced disease. At present, although it is known that there are 
several causative factors in resistance, such as expression of a rapid drug efflux 
protein and non bcr-abl-dependent transformation involving the src family, TDK 
mutations in the chimerical gene are thought to play a major role in resistance 
acquisition3). Therefore, detection of mutations becomes essential in cases 
treated with Imatinib. Moreover, mutations associated with Imatinib therapy 
emerge as a Ph-positive subclone from minimal residual leukemia（MRD）even 
in the hematological remission period 4,5). This indicates the need for highly 
sensitive tests to detect only Ph-positive leukemic clones. To date, several 
methods to analyze mutations including direct and subcloning sequencing have 
been employed, but respective methods have merits and demerits, and are not 
always sensitive6). Recently, to analyze genetic variations (SNPs, Mutations, and 
methylations), a novel melting analysis called high-resolution melting (HRM) with 
an automated instrument and real-time PCR apparatus has been used7, 8). HRM 
is used to characterize samples according to their dissociation profile as they 




mixture samples with mutant and wild-type cells are easily identified by 
differences in melting curve shapes. mutant sequence variants produce a Tm 
shift compared with the wild-type9). In addition, it is a reliable- and closed-tube 
system without high-cost fluorescence probes10, 11). Thus, to introduce HRM 
assays in clinical settings to detect Ph-positive subclones with bcr-abl kinase 
domain mutations, the relevance and validation of the assay prior to direct 
sequencing was studied.  
 
Materials and Methods 
Samples and processing of cDNA 
A total of 19 Ph-positive samples were used, consisting of 10 unlinked and 
already mutation-known specimens, 8 fresh practical samples from 6 patients 
with CML, 2 patients with ALL and one sample from a Ph-positive K562 cell line. 
All patients with Ph-positive leukemias were being treated with Imatinib at  
400-800mg per day and had hematological remission, but were positive for 
bcr-abl real-time RT PCR. As controls, 16 peripheral blood samples from normal 
volunteers and 10 cell lines consisting of HTLV-1-associated cell lines (Hut102, 
KK1, KOB, OMT, MT2, SO4, ST1), T-cell lines of Jurkat and MOLT4, and the 
monocytic line U937 were used. 
The total RNA was extracted from total leukocyte guanidinium thiocyate 
lyates using an RNeasy Mini Kit (Qiagen, Hilden, Germany). cDNA was 
synthesized using oligo-dT primers and Superscript III reverse transcriptase 
(Invtrogene, Carsland, CA, USA). Practical and stocked samples used in this 




the condition of the criteria of the Japanese Association of Laboratory Medicine. 
 
Study Design for HRM assay in the chimerical abl-TDK region: 
 Our study for detection of mutation was designed as the two step manner: firstly, 
genetic alteration screening by HRM analysis (Figure 1), using the LightCycler 
480 (Roche Molecular System, Alameda, CA, USA) for HRM and real-time 
thermal cycling, secondly, only samples positively screened by HRM were 
directly sequenced.  First of all, each sample was examined for bcr-abl 
chimerical status by the conventional method12). If positive for Major or minor 
chimerical types, these bcr-abl kinase domains were selectively amplified, 
generating a fragment of 1504 bp for b2/a2 and 1579 bp for b3/a2, using primers 
previously reported13).  
For HRM analysis, PCR products of 50-250bp length are recommended for best 
discrimination. Therefore, we applied a modified method previously reported by 
Polakova et al10), generating 4 amplicons, designated as HRM1, 2, 3, and 4 of 
220 bp, 225 bp, 239 bp and 241 bp corresponding to nt 629-848, 830-1054, 
1030-12689, and 1266-1506 (NM_005157), respectively. For HRM, a PCR 
reaction was performed in 20 µl reaction volumes containing 1µl of 1/200 diluted 
template generated as described above, Master Mix, Taq DNA Polymerase, 
dNTP Mix, HRM Dye, 3mM MgCl2, primers10), and 1M GC Melt, according to the 
instructions of Roche Applied Science (Manheim, Germany). The PCR was 
monitored by real-time cycling and a strong fluorescent signal was generated 
only when bound to dsDNA, that is the touch down PCR cycling and HRM 




temperature, from 60 to 90℃ at a rate of 100 acquisitions per 1℃. The melting 
status and changes in Tm value were analyzed using the Roche HRM algorithm 
(Gene Scanning Software, Roche Supplied Science, Manheim, Germany), 
depicting graphs of fluorescence-normalized and temperature-shifted melting 




In this study, to compare to accuracy of HRM analysis, regardless of the first 
step negative samples, all of the samples used were confirmed by sequencing 
the regions of the selectively amplified chimerical abl TKD, as well as abl TKD 
from Ph-negative controls using a Big Dye terminator kit Ver 3.1 (Applied 
Biosystems, Carsland, CA, USA) and the ABl Prism 3130 Genetic Analyzer 
(Applied Biosystems) according to the manufacturer’s instructions. 
 
Results 
HRM assay validation: 
For HRM scoring, Ph(+) K562 was set up as a wild-type genotype and the 2 or 
3 normal blood samples were monitored as negative controls. First of all, using 
three different samples with mutations, HRM analysis in duplicate was 
performed, generating constant positive melting curves both in terms of shape 
and peak height with a range of melting temperatures (Tm) from 84-86℃ (Fig 2). 
On the other hand, 16 samples without the Ph-chromosome constantly produced 




in Fig. 3 (Normalized and Temp-shifted melting curves and difference plots).  
Interestingly, as shown in Fig 2 panel-(B), no correlation was observed 
between fluorescence heights and the ratio of the mutant and wild-type: the peak 
was higher in mixture samples with mutant and wild-type cells than samples with 
only mutant clones. To address this strange relation, variable mixture-samples 
with mutant and wild-type cells diluted by exogenous control DNA from wild-type 
cells were subjected to the HRM assay. Fig 4 shows that samples containing 
only mutant cells (bottom graph) produced indeterminate signals with low peaks, 
but the mixture samples containing variable wild-type cell burden (5-90%) 
displayed apparently higher peaks, indicating the existence of mutation. This 
shows that 100% mutant samples may become false negative, with 
indistinguishable from only wild-type patterns. To form only homoduplex dsDNA 
in either mutant or wild-type DNA probably accounted for the indeterminate 
evaluation in all mutant or wild-type samples. 
Accordingly, to avoid false-negatives in samples with all mutant cells, we 
organized screen mutations using two-divided samples; one was an original and 
the other mixed by exogenous wild-type cells, as shown in Fig 5. Using this 
strategy, the test performance of HRM was examined in this study. 
  
HRM assay results 
The HRM assay was blindly examined in duplicate by a single researcher and 
then compared to sequencing data. As summarized in Table 1, the HRM test 
was positive for 13 (72.2%) of 19 Ph-positive leukemias, including a Ph-positive 




14 missense mutations (73.6%) out of 19 Ph(+) leukemias. The positive and 
negative accordance rate of both tests was 94.7% among 19 Ph(+or-) samples. 
The discrepancy in sample No 5, negative in the HRM and positive in the 
sequencing, was expected before HRM analysis, because the PCR efficiency 
was not so good. As expected, the direct sequencing disclosed a problematic 
issue for PCR in that a mutation (nt 838) existed within the annealing sequence 
(nt830-849) of the primer.  
Next, of 26 Ph-negative samples consisting of 10 cell lines and 16 normal blood 
controls, HRM assays produced negative findings in all but one. The positive 
one for HRM was U937 derived from myelomonocytoid leukemic cells. The 
sequencing revealed a mutation of E308V, which was expected to be somatic as 
it is one of the oncogenes. 
 Conclusively, the accordance rate of the two methods was 98.7% in all 45 
cases of Ph-positive/-negative leukemias and controls.  
 
Discussion 
Most patients with Ph-positive leukemias, especially chronic CML, who 
receive Imatinib as first–line therapy achieve good cytogenetic and molecular 
responses. However, long-term molecular studies suggest that around 25-30% 
of patients seem not to achieve successful responses and undergo disease 
progression. Major causes of Imatinib resistance include the emergence of 
leukemic clones with mutations in the tyrosine kinase domain of bcr-abl. This 
indicates that it is necessary to screen for mutations in early phase of the 




consensus when and by which technology the TKD mutations should be 
screened. At present, direct sequencing, denaturing high-performance liquid 
chromatography (D-HPLC), denaturing gradient gel electrophoresis (DGDE), 
allele specific oligonucleotide-polymerase chain reaction (ASO-PCR) and 
pyro-sequencing are available, but the respective methods have merits and 
demerits for practical clinical settings14). A novel technology of HRM with 
development of instruments and saturating intercalating dyes is emerging for 
detection of nucleic acid sequence variations and is now applyed in practical 
diagnostic settings15,16). the two step method allows to avoid the direct sequencing for 
the entire region of all samples. 
In this study, the HRM in our system was shown to efficiently and simply 
differentiate mutations in the chimerical bcr-abl TDK region by using LightCycler 
technology and a software algorithm. In particular, it is noteworthy that mixture 
samples with mutant and wild-type cells was easily and high sensitively 
(approximately 5%) detectable. On the other hand, samples with all mutant cells  
often presents with indeterminate low peaks in difference plots, causing 
confusing interpretations. This is probably the main defect in this HRM 
technology resulting from a dependency on heteroduplex formation due to the 
mixture ratio of the mutant and wild-type. Therefore, to avoid false-negatives 
with samples containing all mutant cells, it was shown that the addition of 
exogenous control DNA was useful (Fig 4 and 5). Actually, since the ratio of 
mutant cells in the samples is unknown in practical samples, we adopted an 
HRM assay system which measures using a double feature; an original one and 




Practical examples are shown in Fig 5, indicating that the mixed sample (left 
panel) makes it easy to discriminate, whereas the change in the positive peak 
pattern was tolerable if a 40%mutant sample was diluted up-to 50%. 
Finally, our HRM results were accordant in all but one out of 45 samples with 
an accordance rate of 98.7% compared with sequencing data. The discrepancy 
in the results in one sample was expected due to an accidental relation between 
the primer and mutation sites, as described above. The quality of HRM is 
thought to be highly dependent on real-time amplification, so that we are now 
revising part of the primer set and appropriate sequence length for HRM.  
Clearly, this is a rapid, simple, accurate screening method using HRM 
technology for chimerical bcr-abl TDK mutations involved in resistance to 
Imatinib. Since resistant Ph-subclones emerge from MRD and increase step by 
step in parallel with the long Imatinib therapy duration, the HRM assay system is 
a suitable and useful method to better manage Ph-positive leukemias, for 
example to decide in dose escalation or cessation of Imatinib, alternation of new 
drugs or different therapies with Dasatinib and bone marrow transplantation.  
Actually, we are applying this method in a routine clinical setting prior to 
sequencing to select only mutation-positive samples. 
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Figures 
Figure 1. Study design of High-Resolution Melting (HRM) and the structure of the 
tyrosine kinase domain (TKD). Firstly, a part of chimerical bcr-abl TKD is 
selectively amplified by nested PCR. Using amplified chimerical bcr-abl 
products as a template, the second PCR for the HRM assay is performed,              
generating four intercalating dye amplicons, HRM-1, -2, -3, and -4. Then, HRM 
analyses were done by using the LightCycler Gene Scanning Application.   
 
Figure 2. Validation of the HRM assay using samples with 100% mutant cells 
and samples with variable % mutant cells. Duplicate assays gave rise to 
the similar results, indicating the good reproducibility in both Normalized 
and Tem-shifted melting curves and difference plots. Ph-positive K562 
cells were used as a wild-type (Wt) reference. 
Figure 3. Validation of HRM test performance using negative controls with 
wild-type TKD demonstrated by direct sequencing  in peripheral blood from 
16 healthy persons and 9 hematopoietic cell lines, excluding the U937 cell 
line. All 4 HRM analyses were evaluated to be wild-type by both 
normalized-Tem shifted melting curves according to the Gene Scanning 
Application Algorithm. Normal peripheral blood from volunteers was used as 
a wild-type reference.  
Figure 4. Changes in heights of peaks and Tm values depending upon the 




revealed indeterminate signals in samples with only mutant cells (around 
100%mutant cell samples). On the other hand, the mixture samples diluted 
up-to 5% mutant cells produced typical positive scanning patterns, indicating 
that the best mixture ratio is 50% vs 50%. 
 
Figure 5. Representative cases (panels A and B) of HRM and sequencing 
analyses. The left panel showed that the addition of wild-type DNA into the 
100% mutant (760T>C) sample made discrimination easy. On the other hand, 
the right panel showed the change in the melting curves between the original 




Table 1. Summary of the results on mutations examined by both HRM and direct 
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sample Clinical dx bcr-ablM Results TKD nt substitute\ exon
Unlikned  1 CML Major Mut Y253F 761 A>T 4
2 CML Major Mut Y253H 760T>C 4
3 CML Major Mut E255E 767A>T 4
4 CML Major Mut E255K 766G>A 4
5 CML Major NE E279K 838G.>A 5
6 CML major Mut T315I 947C>T 6
7 CML major Mut F317L 954C>A 6
8 CML major Mut M351I 1055T>CX 6
9 CML major Mut H396R 1188A>G 7
10 CML major Mut F486S 1461T<C 9
fresh       11 CML major Mut T315I 6
12 CML major Mut F311I 6
13 CML major Mut l370R 7
14 CML major Wt Wt
15 CML major Wt Wt
16 CML major Wt Wt
17 ALL minor Mut Y253H 760T>C 4
18 ALL minor Mt Wt
Cell liness19 K562 minor Wt Wt
20 U937 (-) Mut E308V 926A>T 5
21 KOB (-) Wt Wt
22 KK1 (-) Wt Wt
23 ST1 (-) Wt Wt
24 SO4 (-) Wt Wt
25 OMT (-) Wt Wt
26 MT2 (-) Wt Wt
27 Hut102 (-) Wt Wt
28 Jurkat (-) Wt Wt
29 MOLT4 (-) Wt Wt
Normal PB
30-45 (-) Wt Wt
Table 1
